Scientists around the world are struggling to find a solution to the problem of bacterial multidrug resistance. A new study conducted by the University of Copenhagen using recombinant human proteins shows that even sensitive bacteria produce so-called "drug-resistant strains cells". A comprehensive analysis of this phenomenon helps to better select drug treatments and even stimulate new antibiotic to treat resistant infections of refractory strains.
In a recent issue of the journal Science, Alexander Harms and colleagues from the University of Copenhagen summarized the newly-discovered molecular mechanisms of chronic and recurrent infections caused by surviving bacteria after antibiotic therapy.
"The surprising resilience of bacteria is usually due to dormancy-like physiological state called persistence," says Harms. "At this point, bacteria are resistant to a variety of antibiotics and exogenous drugs. Bacterial cells can convert to bacterial persistence by activating specialized procedures. Once converting to bacterial persistence, the bacteria may be resistant to antibiotic therapy and can even be revived, resulting in recurrence of infection after cessation of antibiotic therapy."
Bacterial persistence, to some extent, is triggered by bacterial toxins that shut down important cellular processes (such as protein synthesis or energy production), forcing bacterial cells into dormant conditions so that they are no longer readily killed by antibiotics. Bacterial persistence is like hibernating animals or spores produced by mushrooms and plants.
These procedures of bacteria are controlled by a regulatory compound known as the "magic spot" and play a central role in bacterial persistence. These important findings will provide a basis for the development of new diagnostic tools and a more effective treatment strategy for a range of bacterial infections. Flarebio provides you with high-quality recombinant proteins like recombinant Ptpra for your research.
没有评论:
发表评论